Catégorie : Pharmacologie

Cannabinoïde Signaling in the Skin : Therapeutic Potential of the “C(ut)annabinoid” System, Kinga Fanni Tóth et al., 2019

Cannabinoïde Signaling in the Skin : Therapeutic Potential of the “C(ut)annabinoid” System Kinga Fanni Tóth, Dorottya Ádám, Tamás Bíró, and Attila Oláh Molecules 2019, 24(5), 918; https://doi.org/10.3390/molecules24050918 Abstract : The endocannabinoid system (ECS) has lately been proven to be an important, multifaceted homeostatic regulator, which influences a wide-variety of physiological processes all over the body. Its members, the endocannabinoids (eCBs; e.g., anandamide), the eCB-responsive receptors (e.g., CB1, CB2), as well as the complex enzyme and transporter apparatus involved in the metabolism of the ligands were shown to be expressed in several tissues, including the skin. Although the best studied functions over the ECS are [...]

Lire la suite

Streets of the ‘spice zombies’: Dependence and poverty stigma in times of austerity, Crime Media Culture, 2019

Streets of the ‘spice zombies’: Dependence and poverty stigma in times of austerity Liviu Alexandrescu School of History, Philosophy and Culture, Oxford Brookes University Crime Media Culture, 2019 Abstract Following the 2016 general ban on new psychoactive substances, synthetic cannabinoids (‘spice’-type drugs) have moved into unregulated street markets and have become popular among homeless populations in the United Kingdom. Images of so-called ‘spice zombies’, rough sleepers in public spaces experiencing severe substance-induced fits, have been used by local and national media to suggest the growing scale of the problem. This article proposes that such depictions should be read through a cultural analysis rooted in the [...]

Lire la suite

A Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects, Lesley Taylor et al., 2018

A Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects Lesley Taylor,·Barry Gidal,·Graham Blakey, Bola Tayo, Gilmour Morrison CNS Drugs, 2018 https://doi.org/10.1007/s40263-018-0578-5 Abstract Background : A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters. Objective : This trial assessed the safety, tolerability and PK of CBD oral solution in healthy adult volunteers, as well as the effect [...]

Lire la suite

Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure, Marco Colizzi et al., 2018

Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure Marco Colizzi, Philip McGuire, Vincent Giampietro, Steve Williams, Mick Brammer, Sagnik Bhattacharyya, European Neuropsychopharmacology, 2018, 28, 850-862. https://doi.org/10.1016/j.euroneuro.2018.04.003 0924-977X/ ©2018 ElsevierB.V. and ECNP. All rights reserved. KEYWORDS : Cannabis use; Delta-9-tetrahydrocannabinol; Functional Magnetic Resonance Imaging; Cognitive functioning; Tolerance; Psychosis Abstract Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main activei ngredient in cannabis, (-)-trans-Δ9 tetrahydrocannabinol (Δ9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, [...]

Lire la suite

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review, Jasmine Turna et al., 2019

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Mary Jean Costello, Mark Weiss, and James MacKillop ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 1-14   Abstract : There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified [...]

Lire la suite

Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands, Tom P. Freeman et al., 2018

Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands Tom P. Freeman, Peggy van der Pol, Wil Kuijpers, Jeroen Wisselink, Ravi K. Das, Sander Rigter, Margriet van Laar, Paul Griffiths, Wendy Swift, Raymond Niesink and Michael T. Lynskey Psychological Medicine, 2018 https://doi.org/10.1017/S0033291717003877   Abstract Background : The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor. Methods : Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from [...]

Lire la suite

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals : implications for psychosis, Marco Colizzi et al., 2019

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis Marco Colizzi, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove,  Sagnik Bhattacharyya Molecular Psychiatry, 15 February 2019 https://doi.org/10.1038/s41380-019-0374-8 Abstract : The neurobiological mechanisms underlying the association between cannabis use and acute or long lasting psychosis are not completely understood. While some evidence suggests altered striatal dopamine may underlie the association, direct evidence that cannabis use affects either acute or chronic striatal dopamine is inconclusive. In contrast, pre-clinical research suggests that cannabis may affect dopamine via modulation of glutamate signaling. A double-blind, randomized, placebo-controlled, crossover design was used to investigate whether altered [...]

Lire la suite

Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans, Marco Colizzi et al., 2019

Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans Marco Colizzi, NathalieWeltens, Philip McGuire, Lukas Van Oudenhove and Sagnik Bhattacharyya Brain Sciences, 2019, 9, 93 doi:10.3390/brainsci9040093 Abstract : Background : Cannabis use can increase the risk of psychosis, and the acute administration of its key psychoactive ingredient, delta-9-tetrahydrocannabinol (D9-THC), can induce transient psychotomimetic symptoms. Methods: A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic eects of acute intravenous administration of D9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure. Results : In the 20 min following acute D9-THC administration, symptomatic eects of at [...]

Lire la suite

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, Daniele Piomelli , 2015

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 44-46 https://doi.org/10.1089/can.2015.29003.ebr   Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held faculty appointments in [...]

Lire la suite

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain, Natasha R. Ryz et al., 2017

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain Natasha R. Ryz, David J. Remillard, Ethan B. Russo Cannabis and Cannabinoid Research, 2017, 2, 1, ReviewOpen Access https://doi.org/10.1089/can.2017.0028 Abstract Introduction: The roots of the cannabis plant have a long history of medical use stretching back millennia. However, the therapeutic potential of cannabis roots has been largely ignored in modern times. Discussion: In the first century, Pliny the Elder described in Natural Histories that a decoction of the root in water could be used to relieve stiffness in the joints, gout, and related conditions. By the 17th century, various herbalists were recommending cannabis root [...]

Lire la suite